Effects of 3,4-diaminopyridine on myasthenia gravis: Preliminary results of an open-label study

Background: 3,4-diaminopyridine (3,4-DAP) can lead to clinical and electrophysiological improvement in myasthenic syndrome; it may thus represent a valuable therapeutic option for patients intolerant to pyridostigmine. Objective: to assess 3,4-diaminopyridine (3,4-DAP) effects and tolerability in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ceccanti, Marco, Libonati, Laura, Ruffolo, Gabriele, Cifelli, Pierangelo, Moret, Federica, Frasca, Vittorio, Palma, Eleonora, Inghilleri, Maurizio, Cambieri, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424766/
https://www.ncbi.nlm.nih.gov/pubmed/36052140
http://dx.doi.org/10.3389/fphar.2022.982434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424766/
https://www.ncbi.nlm.nih.gov/pubmed/36052140
http://dx.doi.org/10.3389/fphar.2022.982434

Ejemplares similares